Clinical trial
XK469R in Treating Patients With Refractory Hematologic Cancer
NCT00095797 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00095797 |
|---|---|
| Title | XK469R in Treating Patients With Refractory Hematologic Cancer |
| Official title | A Phase I Study of XK469R (NSC 698215) in Patients With Refractory Hematologic Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13 and 22 more |
| Intervention type | Drug, Other |
| Interventions | R(+)XK469, pharmacological study, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Oct 1, 2004 |
| Primary completion | Mar 1, 2007 |
| First posted | Nov 9, 2004 |
| Last update posted | Feb 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: